KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

Check the time stamp on this data. Updated AI-Generated Signals for Protagonist Therapeutics Inc. (PTGX) available here: PTGX ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

John Hussman Reduces Stake in Barrick Gold Corp by 68%, Impacting Portfolio by -2.11% John Hussman ( Trades, Portfolio) added ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protagonist Therapeutics (NASDAQ:PTGX) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the ...

Protagonist Therapeutics, Inc. (PTGX) stock price is 38.36 and Protagonist Therapeutics, Inc. (PTGX) 10-day simple moving average is 37.22. Protagonist Therapeutics, Inc. (PTGX) stock price is 38. ...